reviewed april 2026|next review october 2026|88 physicians psi has verified|2866 published studies
Kisspeptin-54 (Metastin)
Kisspeptin-54 is the full-length 54-amino acid isoform of kisspeptin (formerly called metastin), the naturally occurring (the body's own) master regulator of the reproductive hormone axis, with clinical research led by the Dhillo laboratory demonstrating its potential as a safer IVF trigger and diagnostic tool for reproductive disorders.
Evidence landscape: 2866 published studies
Published studies span reproductive endocrinology, IVF medicine, and sexual neuroscience. Multiple completed human studies from the Dhillo laboratory.
- 51 Human
- 102 Animal
- 47 Reviews
- 2666 Other research
Not FDA-approved. Under clinical investigation for IVF oocyte maturation triggering and reproductive diagnostics. Multiple human studies completed but no regulatory submission has been made.
Not available as a therapeutic product. Used in clinical research settings. For the full overview of kisspeptin biology, see PSI's kisspeptin page.
Kisspeptin-54 is the full-length naturally occurring (the body's own) form of kisspeptin. Shorter fragments (kisspeptin-10) also activate KISS1R but have shorter half-lives. Kisspeptin-54 triggers the body's own LH surges rather than providing exogenous LH-like stimulation, which may reduce ovarian hyperstimulation risk in IVF.
PSI Assessment
In IVF, triggering oocyte maturation with hCG carries a risk of ovarian hyperstimulation syndrome (OHSS), a potentially dangerous complication. Kisspeptin-54 offers a different approach: instead of providing an external LH-like signal, it triggers the body's own LH surge through the reproductive control center. Clinical studies from the Dhillo laboratory at Imperial College London have demonstrated that kisspeptin-54 can trigger oocyte maturation with a lower OHSS risk profile. The compound is also being used as a diagnostic probe for reproductive disorders and has shown effects on sexual brain circuits in fMRI studies.
Triggers the body's own LH surge rather than providing exogenous stimulation. Clinical data supports a lower OHSS risk profile for IVF triggering. Also being developed as a reproductive diagnostic tool.
The mechanism centers on KISS1R (GPR54) activation in hypothalamic GnRH neurons. Kisspeptin-54 is the most potent naturally occurring (the body's own) ligand for this receptor. Binding triggers Gq/11 signaling, phospholipase C activation, and IP3-mediated calcium release, leading to GnRH neuron depolarization and pulsatile GnRH secretion. This drives LH and FSH release from the anterior pituitary. The 54-amino acid form has a longer plasma half-life than kisspeptin-10 due to slower proteolytic degradation, producing more sustained gonadotropin responses.
What the evidence supports
Kisspeptin-54 reliably triggers LH surges in humans through KISS1R/GnRH pathway activation. Clinical studies from the Dhillo laboratory demonstrate IVF oocyte maturation triggering with reduced ovarian hyperstimulation syndrome (OHSS) risk compared to hCG. fMRI studies document enhanced limbic brain responses to sexual stimuli. Genetic studies confirm the essential role of the KISS1R pathway in human reproduction.
What is not yet established
Clinical superiority over hCG for IVF triggering in terms of pregnancy rates. FDA approval for any reproductive indication. Whether the fMRI-observed sexual brain effects translate to meaningful clinical outcomes for desire disorders. Optimal dosing and timing protocols for IVF applications.
Research Evidence
The findings below cover the IVF trigger application, the reproductive diagnostic use, and the sexual neuroscience research.
Evidence by condition
Evidence dimensions across IVF triggering, reproductive diagnostics, and sexual neuroscience. The IVF application has the deepest clinical evidence.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Reproductive Diagnostics | ||||
| IVF Oocyte Maturation | ||||
| Puberty Biology | ||||
| Hypothalamic Amenorrhea |
Clinical studies demonstrate that kisspeptin-54 can trigger oocyte maturation in IVF with a lower risk of ovarian hyperstimulation syndrome compared to hCG trigger, by stimulating the body's own LH surge rather than providing exogenous LH-like stimulation.
The IVF trigger application is the most clinically advanced use case. Phase III confirmation is needed. Whether kisspeptin-54 matches hCG in terms of oocyte yield is being evaluated.
Intravenous kisspeptin-54 infusion reliably triggers LH pulses in healthy subjects and can be used to probe GnRH neuron function, helping diagnose hypothalamic amenorrhea and evaluate reproductive axis integrity.
The diagnostic application provides a physiological test of GnRH neuron responsiveness. This is investigational and not part of standard clinical evaluation.
fMRI studies show kisspeptin-54 infusion enhances limbic brain activation (amygdala, cingulate) in response to sexual stimuli in both men and women, suggesting a role in sexual arousal circuitry beyond reproductive hormone regulation.
Whether these brain imaging effects translate to clinical treatment for sexual desire disorders is theoretical. The fMRI effects do not establish clinical efficacy.
51 Human|102 Animal|47 Reviews
View all 2866 indexed studiesHow Kisspeptin-54 (Metastin) Works
Kisspeptin-54 is the naturally occurring (the body's own) full-length kisspeptin isoform. It activates KISS1R/GPR54 on hypothalamic GnRH neurons, triggering pulsatile GnRH secretion that drives LH and FSH release from the anterior pituitary.
Kisspeptin-54 is the full-length version of the kisspeptin hormone. It sends the strongest signal to the brain's reproductive control center, triggering a cascade that releases LH, FSH, and ultimately testosterone or estrogen. Shorter fragments (kisspeptin-10) also work but kisspeptin-54 has a longer duration of action.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Kisspeptin-54 (formerly metastin) binds KISS1R/GPR54 with high affinity. It is the most potent naturally occurring ligand for this receptor. The 54-amino acid form has longer plasma half-life than kisspeptin-10 due to slower proteolytic degradation. Both forms stimulate GnRH release but kisspeptin-54 produces more sustained gonadotropin responses.
What is Kisspeptin-54 (Metastin) being studied for?
Researchers are studying Kisspeptin-54 (Metastin) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Kisspeptin-54 (Metastin) overall. This means a compound can have human studies for one condition but only animal data for another.
Reproductive Diagnostics
·Human TrialsKisspeptin-54 infusion reliably triggers LH pulses and can probe GnRH neuron function for diagnosing hypothalamic amenorrhea and evaluating reproductive axis integrity.
Limitations: Diagnostic use is investigational. Not part of standard clinical evaluation protocols.
IVF Oocyte Maturation
·Animal StudiesClinical studies show kisspeptin-54 can trigger oocyte maturation in IVF with lower ovarian hyperstimulation syndrome risk compared to hCG. Triggers the body's own LH surge rather than exogenous stimulation.
Limitations: Not FDA-approved. Phase III confirmation is needed. Whether oocyte yield and pregnancy rates match hCG-triggered cycles is still being evaluated.
Puberty Biology
·Animal StudiesLoss-of-function mutations in KISS1R cause hypogonadotropic hypogonadism, confirming the essential role of kisspeptin signaling in puberty onset and reproductive function.
Limitations: The genetic evidence validates the pathway but therapeutic applications for puberty disorders using kisspeptin-54 have not been developed.
Hypothalamic Amenorrhea
·Animal StudiesKisspeptin-54 can restore LH pulsatility in women with hypothalamic amenorrhea (absent periods due to hypothalamic dysfunction), demonstrating that the GnRH neurons retain responsiveness.
Limitations: Therapeutic use for hypothalamic amenorrhea is investigational. The short half-life limits sustained therapeutic application without modified delivery.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Under clinical investigation for IVF and reproductive diagnostics. Multiple human studies completed with favorable safety profiles.
Availability: Not available as a therapeutic product. Used in clinical research settings only. See PSI's kisspeptin page for the full biological overview.
Class context: Kisspeptin-54 has been well tolerated in clinical studies. Mild flushing is the most commonly reported side effect. The physiological mechanism (stimulating the body's own LH rather than providing exogenous LH) may inherently carry a lower OHSS risk profile for IVF triggering.
Kisspeptin-54 has been well tolerated across clinical studies with mild flushing as the most common side effect. The physiological approach to LH surge induction may offer inherent safety advantages over exogenous hCG for IVF triggering.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Kisspeptin-54 (Metastin) discussion.
Comparison and Related Research
Kisspeptin-54 is compared with related reproductive peptides and the shorter kisspeptin-10 fragment.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.First-in-human study demonstrating that intravenous kisspeptin-54 potently stimulates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release in healthy men. A single bolus injection produced rapid, dose-dependent increases in gonadotropin levels, confirming the peptide's role as a key upstream regulator of the reproductive axis in humans.Dhillo WS et al., 2005 in J Clin Endocrinol Metab. View on PubMed
- 2.Proof-of-concept clinical trial using kisspeptin-54 as an alternative trigger for oocyte maturation in women undergoing IVF. Subcutaneous kisspeptin-54 successfully induced egg maturation and live births while carrying a lower risk of ovarian hyperstimulation syndrome compared to conventional hCG triggers.Jayasena CN et al., 2014 in J Clin Invest. View on PubMed
- 3.Clinical study administering subcutaneous kisspeptin-54 to women with hypothalamic amenorrhea, a condition where the reproductive axis is suppressed. Treatment restored gonadotropin pulses and significantly increased LH and FSH levels, demonstrating therapeutic potential for conditions involving hypogonadotropic hypogonadism.Jayasena CN et al., 2011 in J Clin Endocrinol Metab. View on PubMed
- 4.Expanded clinical trial of kisspeptin-54 as an IVF trigger in 60 women at high risk of ovarian hyperstimulation. No patient developed moderate or severe OHSS, and the ongoing pregnancy rate was comparable to historical controls, supporting the safety advantage of kisspeptin-54 over hCG in high-risk populations.Abbara A et al., 2018 in J Clin Invest. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.